Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is a common malignancy, and more than 70% of newly diagnosed
HCC patients already have advanced disease. Sorafenib and lenvatinib are recommended as
first-line options for advanced HCC. The PD-1 monoclonal antibody，such as nivolumab and
pembrolizumab, have been approved to treat the patients with advanced HCC by the FDA.
Combining radiotherapy with immune checkpoints showed promising response rates and improved
survival in several solid tumor types. The purpose of this randomized study is to determine
whether stereotactic body radiation therapy (SBRT) combined with sintilimab (an anti-PD-1
antibody) will improve the response to the anticancer treatment compared to sintilimab alone
in patients with advanced HCC.
About 84 participants will be enrolled in this study. All will take part at West China
Hospital, Sichuan University.